These agents target immune-cell-surface checkpoint proteins, including the cytotoxic T-lymphocyte-associated protein-4 (CTLA4) and the programmed death-1/programmed death ligand-1 (PD-1/PD-L1), which inhibit anti-cancer immune responses. The gene discussed is CTLA4; the disease is cancer.